Lower-dose chemotherapy before CAR T-cell therapy in people with kidney problems
Tests adjusted chemotherapy before CAR T-cell therapy in adults with B-cell cancers.
Plain-language title generated from the registry record
Registry title: CAR T-cell Therapy in Patients With Renal Dysfunction
Key facts
- Where
- Atlanta, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Caitlin GuzowskiAtlanta, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northside Hospital, Inc.
- Trial code
- NCT05909059
- Record updated
- 14 October 2026
- Original description
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.Read full original descriptionShow less
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Inclusion: Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma; Adequate bone marrow function to receive lymphodepleting chemotherapy; Renal function </= 60mL/min/1.73m2; ECOG 0-2.
Exclusion: Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator; Use of therapeutic dose systemic corticosteroids (defined as >20mg/day prednisone or equivalent) within 72 hours of CAR-T administration; Relative CNS disorders.